11.43MMarket Cap
LossP/E TTM
Key Figures
2.950Open
2.950High
50.19KVolume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
1.29%Turnover Ratio
2.840Prev. Close
2.770Low
68.57KTurnover
LossP/E Static
1.65P/B
0.00%Div Yield TTM
-214.57%ROA
52.00052wk High
0.97Volume Ratio
-14.20MNet Profit
3.89MShares
-7.5211EPS TTM
0.37Beta
-984.82%ROE
2.85052wk Low
6.34%Amplitude
--Gross Margin
11.43MMarket Cap
-2.07Reward/Risk
9.23%Risk Rate
Currency: USD Updated: 2026-07-31 Key Insights
Quantum BioPharma Ltd's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 154 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.50.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Quantum BioPharma Ltd's Score
Support & Resistance

Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Quantum BioPharma Ltd Highlights
StrengthsRisks
Quantum BioPharma Ltd News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Quantum BioPharma Ltd
QNTM
1
Ionis Pharmaceuticals Inc
IONS
25
Indicators
Financial Indicators
EPS

Relevant data have not been disclosed by the company yet.
Total revenue

Relevant data have not been disclosed by the company yet.
Quantum BioPharma Ltd Info
Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The Company has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
Ticker SymbolQNTM
CompanyQuantum BioPharma Ltd
CEOKotra (Lakshmi P)
Websitehttps://www.quantumbiopharma.com/
Shareholders
FAQs
What is the current price of Quantum BioPharma Ltd (QNTM)?
The current price of Quantum BioPharma Ltd (QNTM) is 2.94.
What is the symbol of Quantum BioPharma Ltd?
The ticker symbol of Quantum BioPharma Ltd is QNTM.
What is the 52-week high of Quantum BioPharma Ltd?
The 52-week high of Quantum BioPharma Ltd is 52.00.
What is the 52-week low of Quantum BioPharma Ltd?
The 52-week low of Quantum BioPharma Ltd is 2.85.
What is the market capitalization of Quantum BioPharma Ltd?
The market capitalization of Quantum BioPharma Ltd is 11.43M.
Is Quantum BioPharma Ltd (QNTM) currently rated as Buy, Hold, or Sell?
According to analysts, Quantum BioPharma Ltd (QNTM) has an overall rating of Buy, with a price target of 12.50.
What is the Earnings Per Share (EPS TTM) of Quantum BioPharma Ltd (QNTM)?
The Earnings Per Share (EPS TTM) of Quantum BioPharma Ltd (QNTM) is -7.97.